IDH1 and neoplasm: Given that irreversible genetic and epigenetic alterations occur in mutant IDH-dependent reprogramming during tumor progression [53,85] (Figure 2), determining the timing and the scheduling of the mutant IDH inhibitors may be a critical challenge for maximizing their efficacy in IDH-mutant gliomas.